Grimes & Company, Inc. Iovance Biotherapeutics, Inc. Transaction History
Grimes & Company, Inc.
- $3.66 Billion
- Q3 2024
A detailed history of Grimes & Company, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 33,625 shares of IOVA stock, worth $287,493. This represents 0.01% of its overall portfolio holdings.
Number of Shares
33,625
Previous 33,375
0.75%
Holding current value
$287,493
Previous $267,000
17.98%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding IOVA
# of Institutions
314Shares Held
241MCall Options Held
3.77MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA27.3MShares$234 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY26.6MShares$228 Million6.53% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$205 Million28.52% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$181 Million0.0% of portfolio
-
State Street Corp Boston, MA13.2MShares$113 Million0.01% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.35B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...